The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the referen ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products ...

However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new cancer ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with p ...

FORT WORTH, Texas — A Fort Worth teen was shot and killed while celebrating his 19th birthday overnight Sunday, police said. Officers responded to a shooting call around 12:30 a.m. Sunday in the ...